Effects of a Novel Dispersible Supplement Containing of Vitamin D and of B12 in Restoring Vitamin D and B12 Insufficiency: A Multicenter, Randomized Controlled Trial.

Plain-language guide to PMID 39940277 (2025): multicenter randomized controlled trial of Vitamin D, K2, Magnesium and Zinc and Copper (Supplement).

Key Facts

PMID: 39940277
Journal: Nutrients
Year: 2025
Study type: Randomized Controlled Trial
Authors: Angelopoulos N et al. (5 authors)
DOI: 10.3390/nu17030419

What This Study Did, in Plain Language

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc and Copper (Supplement) in this randomized controlled trial publication.

Vitamins D and B12 play a crucial role in maintaining bone health, immune function, and neurological integrity.

Combined deficiencies in these vitamins can lead to severe health consequences.

Current treatment approaches, such as dietary changes and single-vitamin supplementation, often fail to address these deficiencies comprehensively.

Who Took Part

PubMed indexes the participants as young adults, adults, middle-aged adults, older adults and people over 80, both men and women.

Participants aged 20 to 80 years, with insufficient levels of 25-hydroxyvitamin D (serum < 20 ng/mL) and B12 (serum < 250 ng/L), were eligible for inclusion.

How the Study Was Run

In design terms this was a randomized and multicenter study.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Running at several centres spread the Vitamin D, K2, Magnesium and Zinc study over different clinics and patient groups.

A prospective, multicenter, randomized controlled trial was conducted in Greece from October 2024 to December 2024.

What Was Measured

Topics PubMed links to this paper include Dietary Supplements, Vitamin D, Vitamin B 12, Vitamin D Deficiency, Vitamin B 12 Deficiency and Greece.

The authors tagged it with the keywords vitamin B12 and vitamin insufficiency.

What This Means in Plain Language

The paper is a randomized and multicenter study of Vitamin D, K2, Magnesium and Zinc and Copper (Supplement).

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Nutrients), a journal based in Switzerland.

More context: the Vitamin D, K2, Magnesium and Zinc compound page and the Copper (Supplement) compound page, all human trials.

Our Notes on the Compounds

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.